PHARMACISTS are being urged to advise patients aged 70-79 that they are eligible to access shingles vaccine from their GP under the National Immunisation Program.
The most frequent debilitating complication of shingles is post herpetic neuralgia (PHN) - pain that continues after the rash has healed.
Zostavax is marketed in Australia by CSL offshoot Seqirus.
The above article was sent to subscribers in Pharmacy Daily's issue from 09 May 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 09 May 18